|
|
Article: Corixa Cuts Staff, Sells Some Technology Assets To Medarex.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Corixa Corp. said it restructured its South San Francisco operations by reducing its work force there by about 60 percent, and completed a $21 million deal with Medarex Inc. to sell certain technology and preclinical therapeutic programs.
The moves, following additional delays for Corixa's lead product, Bexxar, will result in a narrowing of the company's focus to immunotherapeutics.
Seattle-based Corixa reduced its South San Francisco staff of about 200 by about 130 people, including the elimination of positions that had been planned but left unfilled after the delay with Bexxar, said Michelle Burris, Corixa's senior vice president ...